In Law360, Health Care Attorneys Examine State Drug Pricing Reforms

In The News
November 25, 2020

Drug pricing is at the forefront of U.S. health policy and a topic of interest at the federal and state level. In the second installment of a three-part series in Law360 on drug pricing reform, health care partner Deborah Kantar Gardner and counsel Peter Holman Jr. review the status of key state drug pricing reforms, where some of the more immediate impacts of drug pricing are occurring.

The authors analyzed four common state initiatives: drug pricing transparency; pharmacy benefit manager controls; drug importation; and value-based arrangements.